Lp-PLA2
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Lp-PLA2 is vascular-specific inflammation — hsCRP is not. hsCRP rises with any inflammatory state: obesity, infection, autoimmune disease, metabolic syndrome. Lp-PLA2 is produced predominantly within atherosclerotic plaques by plaque macrophages. Elevated Lp-PLA2 is therefore a more direct signal of active, inflamed arterial disease.
- Lp-PLA2 is a particularly strong predictor of stroke risk. Multiple prospective studies have found that Lp-PLA2 is a stronger independent predictor of ischemic stroke than coronary events — possibly because the carotid and cerebrovascular plaques that cause stroke are particularly prone to the type of macrophage-driven inflammation that generates Lp-PLA2.
- Lp-PLA2 and hsCRP together identify high-risk subgroups. The combination of elevated Lp-PLA2 and elevated hsCRP identifies individuals at substantially higher cardiovascular risk than either marker alone. Normal hsCRP with elevated Lp-PLA2 identifies a group with vascular-specific inflammation that systemic markers would miss.
- Statin therapy reduces Lp-PLA2. Statins lower Lp-PLA2 activity by 20–30% — an effect thought to contribute to statins' plaque-stabilizing (beyond just LDL-lowering) benefits. This reduction in Lp-PLA2 may partially explain why statins reduce cardiovascular events more than their LDL-lowering effect alone would predict.
- Darapladib — a direct Lp-PLA2 inhibitor — failed to reduce cardiovascular events in large trials, raising questions about whether Lp-PLA2 is a cause or a marker of plaque vulnerability. Current consensus is that it is a highly informative marker regardless of its causal role.
The Plaque Inflammation Test That hsCRP Cannot Replace
C-reactive protein has become the default inflammation marker in cardiovascular risk assessment — and for good reason. hsCRP is cheap, widely available, and adds meaningful predictive value to standard lipid panels. But hsCRP has a fundamental limitation: it measures systemic inflammation from any source. Obesity, a recent infection, rheumatoid arthritis, and active atherosclerotic plaques all elevate hsCRP indistinguishably.
Lp-PLA2 solves a different problem. Because it is produced specifically by macrophages within atherosclerotic lesions — and circulates bound to LDL rather than as a free acute phase reactant — it reflects the inflammatory activity occurring inside arterial plaques rather than the body's overall inflammatory state. This specificity is clinically meaningful: plaque inflammation, not just plaque size, is what determines whether a plaque is stable or vulnerable to rupture.
The landmark STABILITY trial and multiple prospective cohort studies have established that Lp-PLA2 is an independent predictor of cardiovascular events after adjustment for conventional risk factors, LDL, and hsCRP. The predictive value is additive to hsCRP — the two markers capture different dimensions of cardiovascular inflammation risk.
How Lp-PLA2 Drives Plaque Vulnerability
The mechanism by which Lp-PLA2 contributes to atherosclerosis is well-characterized. Within developing plaques, macrophages engulf oxidized LDL and become foam cells — the lipid-laden cells that form the necrotic core of vulnerable plaques. These macrophages secrete Lp-PLA2, which hydrolyzes oxidized phospholipids in the plaque microenvironment, generating two highly pro-inflammatory products: lysophosphatidylcholine (lyso-PC) and oxidized non-esterified fatty acids (ox-NEFAs).
These products amplify the inflammatory cascade within the plaque: lyso-PC recruits additional monocytes into the plaque, promotes macrophage activation, and induces endothelial dysfunction; ox-NEFAs drive further oxidative stress and inflammatory signaling. The net effect is a positive feedback loop in which Lp-PLA2 activity promotes plaque inflammation, which promotes more Lp-PLA2 production — a cycle associated with plaque destabilization and rupture risk.
A meta-analysis of 32 prospective studies including 79,036 participants found that each standard deviation increase in Lp-PLA2 activity was associated with a 10% increase in coronary heart disease risk and a 12% increase in stroke risk, independent of conventional risk factors. 1
| Level | Activity Range | Interpretation | Notes |
|---|---|---|---|
| Optimal | < 175 nmol/min/mL | Low plaque inflammatory activity | Lower half of normal range; lowest event rates |
| Borderline | 175–200 nmol/min/mL | Moderate — monitor and optimize | Anti-inflammatory lifestyle; retest in 6 months |
| Elevated | 200–225 nmol/min/mL | Above optimal — intervention warranted | Evaluate full CV risk; consider statin therapy |
| High | > 225 nmol/min/mL | High vascular inflammatory burden | Aggressive CV risk management; cardiology evaluation |
Already have your lab results? See how your Lp-PLA2 and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →Lp-PLA2 and the Multi-Marker Cardiovascular Picture
Lp-PLA2 is most valuable not as a standalone test but as part of a multi-marker cardiovascular risk evaluation. The combination of markers that provides the most comprehensive picture:
ApoB + Lp-PLA2: High ApoB means many atherogenic particles available to deposit in arterial walls; high Lp-PLA2 means the plaques that have formed are actively inflamed. This combination represents both high plaque-building risk and high plaque-rupture risk — the most actionable cardiovascular risk signal in the lipid and inflammation space.
hsCRP + Lp-PLA2: When both are elevated, systemic and vascular inflammation are both active — the highest-risk pattern. When hsCRP is normal but Lp-PLA2 is elevated, the signal is more specifically vascular — worth pursuing even without systemic inflammatory markers driving clinical concern.
Lipoprotein(a) + Lp-PLA2: Lp(a) itself is pro-inflammatory and promotes oxidized phospholipid accumulation in plaques — one of the reasons it is so strongly atherogenic. Elevated Lp(a) combined with elevated Lp-PLA2 suggests that Lp(a)-driven plaque inflammation may be active, a pattern seen in high-risk familial cardiovascular disease.
Sources
- Lp-PLA2 Studies Collaboration. "Lipoprotein-Associated Phospholipase A2 and Risk of Coronary Disease, Stroke, and Mortality." The Lancet, 2010. PubMed →
| Range Type | Value (nmol/min/mL (activity) or ng/mL (mass)) | Notes |
|---|---|---|
| Standard Clinical Range | Activity: < 225 nmol/min/mL · Mass: < 200 ng/mL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Activity: < 175 nmol/min/mL · Mass: < 150 ng/mL |
Associated with reduced all-cause mortality and extended healthspan.
Lp-PLA2 can be measured as either activity (nmol/min/mL) or mass (ng/mL) — the two assays are related but not interchangeable, and reference ranges differ. Activity assays are more commonly used clinically. Within the normal range, values in the lower half are associated with significantly lower plaque inflammatory activity and cardiovascular event rates. Lp-PLA2 is particularly informative when combined with hsCRP: normal hsCRP with elevated Lp-PLA2 suggests vascular-specific inflammation without systemic inflammatory signal — a pattern that warrants cardiovascular evaluation.
|
Already have your results? See what your Lp-PLA2 and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
How does Lp-PLA2 differ from hsCRP as an inflammation marker?
hsCRP (high-sensitivity C-reactive protein) is an acute phase reactant produced by the liver in response to any inflammatory signal — infection, injury, metabolic syndrome, autoimmune disease, or vascular disease. It reflects the body's overall inflammatory state. Lp-PLA2 is produced predominantly by macrophages within atherosclerotic plaques and circulates bound to LDL. It is generated specifically in response to the oxidized phospholipids that accumulate in arterial plaques, making it a more tissue-specific marker of vascular inflammation. This distinction means the two markers can diverge: a person with severe metabolic syndrome and systemic inflammation may have high hsCRP with low Lp-PLA2 (if their plaques are not particularly active); a person with active, vulnerable coronary plaques may have elevated Lp-PLA2 with normal hsCRP. Both markers add independent predictive value and are most informative when interpreted together.
Why does Lp-PLA2 predict stroke more strongly than heart attack?
The precise reason for Lp-PLA2's relatively stronger association with stroke risk compared to coronary risk is not fully established, but several hypotheses exist. Carotid artery plaques — the principal source of emboli causing ischemic stroke — may have a particularly macrophage-rich, inflammatory composition that generates more Lp-PLA2. Small vessel cerebrovascular disease, which contributes substantially to stroke risk, may also involve a pattern of inflammation that is better captured by Lp-PLA2 than by lipid markers. Additionally, traditional lipid markers like LDL and ApoB are stronger predictors of coronary risk, potentially leaving Lp-PLA2 to explain more of the residual (non-lipid-mediated) stroke risk in population studies. Clinically, elevated Lp-PLA2 in someone with carotid bruits, atrial fibrillation, or prior TIA should be taken particularly seriously.
Does diet affect Lp-PLA2?
Yes, though the effect is modest compared to pharmacological interventions. Anti-inflammatory dietary patterns — particularly Mediterranean-style diets rich in olive oil, fish, vegetables, and nuts — are associated with lower Lp-PLA2 activity. Omega-3 fatty acids (EPA and DHA) modestly reduce Lp-PLA2, likely through their effects on macrophage inflammatory signaling. Conversely, diets high in saturated fat and refined carbohydrates — which promote LDL oxidation and macrophage activation — are associated with higher Lp-PLA2 activity. Statin therapy has the most consistent and substantial effect on Lp-PLA2, reducing activity by 20–30% independent of LDL lowering. Niacin and fibrates also reduce Lp-PLA2 modestly. Weight loss in obese individuals reduces Lp-PLA2, reflecting reduced macrophage inflammatory activity that accompanies visceral fat reduction.
What should I do if my Lp-PLA2 is elevated?
An elevated Lp-PLA2 should be interpreted in the context of your full cardiovascular risk profile. If it is elevated alongside high ApoB, elevated hsCRP, hypertension, diabetes, or a strong family history of cardiovascular disease, it adds meaningful weight to the case for aggressive cardiovascular risk management — including statin therapy, blood pressure optimization, and lifestyle intervention. If it is isolated (elevated Lp-PLA2 with otherwise low cardiovascular risk markers), it warrants attention and follow-up but not necessarily immediate pharmacological treatment. Consider increasing omega-3 fatty acid intake, adopting an anti-inflammatory dietary pattern, and retesting in 3–6 months. If you have any symptoms suggesting coronary or cerebrovascular disease (exertional chest pain, TIA symptoms, carotid bruit), elevated Lp-PLA2 combined with those symptoms warrants prompt cardiology or neurology referral.
Is the PLAC test the same as Lp-PLA2?
Yes — the PLAC test is the commercial name for the Lp-PLA2 activity assay developed by diaDexus. It was the first Lp-PLA2 assay to receive FDA clearance (in 2003 for coronary artery disease risk assessment, expanded in 2005 to include stroke risk in CAD patients). The terms PLAC test and Lp-PLA2 activity test are used interchangeably in clinical practice, though there is also a separate Lp-PLA2 mass assay (measuring the amount of the enzyme rather than its activity) that uses different reference ranges. When ordering, specifying 'Lp-PLA2 activity' or 'PLAC test' will get you the most commonly used and validated assay.